Titan BiotechBOM:524717 +2.62%58 Current Ratio is 3.28 as of Mar. 2026, which is 3% above its 10-year median of 3.17. GuruFocus rates BOM:524717 with a GF Score™ of 58/100 and a GF Value™ of ₹144.74 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Titan Biotech ranks worse than 55.07% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Titan Biotech's current ratio for the quarter that ended in Mar. 2026 was 3.28.
Titan Biotech has a current ratio of 3.28. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Titan Biotech's Current Ratio or its related term are showing as below:
BOM:524717'
s Current Ratio Range Over the Past 10 Years
Min: 2.16 Med: 3.17 Max: 4.46
Current: 3.28
During the past 13 years, Titan Biotech's highest Current Ratio was 4.46. The lowest was 2.16. And the median was 3.17.
BOM:524717's Current Ratio is ranked worse than 55.07% of 1411
companies
in the Biotechnology industry
Industry Median: 3.88
vs BOM:524717: 3.28
Titan Biotech (BOM:524717) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Titan Biotech Current Ratio Related Terms
Titan Biotech Current Ratio Historical Data
* Premium members only.
The historical data trend for Titan Biotech's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524717 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Titan Biotech's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Titan Biotech Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Titan Biotech's Current Ratio distribution charts can be found below:
* The bar in red indicates where Titan Biotech's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Titan Biotech (BOM:524717) has a Current Ratio of 3.28 as of Mar. 2026. This is near median its historical median of 3.17. Over the past decade, Titan Biotech's Current Ratio has ranged from 2.16 to 4.46. According to the industry distribution chart, Titan Biotech ranks #777 out of 1411 companies in the Biotechnology industry, placing it in the top 55.1%.
Is Titan Biotech's Current Ratio too high?
Titan Biotech's current Current Ratio of 3.28 is near median its 10-year median of 3.17. Over the past 10 years, this metric has ranged from a low of 2.16 to a high of 4.46. The Biotechnology industry median Current Ratio is 3.88. Titan Biotech's value of 3.28 is 15.5% below this industry median. Based on the distribution chart, Titan Biotech ranks #777 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Titan Biotech has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Titan Biotech's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Titan Biotech ranks #777 out of 1411 companies for Current Ratio. This places Titan Biotech in the lower half of its industry. The industry median Current Ratio is 3.88. Titan Biotech's value of 3.28 is 15.5% below this benchmark. Historically, Titan Biotech's own Current Ratio has ranged from 2.16 to 4.46 over the past decade. While the company's 10-year median is 3.17 vs. the industry median of 3.88, Titan Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Titan Biotech's current Current Ratio of 3.28 is 15.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Titan Biotech's current Current Ratio is 3.28, which is near median its own 10-year median of 3.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Titan Biotech stock overvalued right now?
Based on GuruFocus' analysis, Titan Biotech (BOM:524717) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹144.74, compared to a current price of ₹400.95 — trading 177% above its estimated fair value. The current Current Ratio is 3.28, which is near median its 10-year median of 3.17 and 15.5% below the Biotechnology industry median of 3.88. Titan Biotech's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Titan Biotech (BOM:524717), the current Current Ratio is 3.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Titan Biotech (BOM:524717) Overvalued in 2026?
Based on GuruFocus' analysis, Titan Biotech stock appears to be overvalued.
The current stock price of ₹400.95 is trading 177% above its estimated GF Value™ of ₹144.74.
GuruFocus considers Titan Biotech to be Significantly Overvalued.
Key valuation signals for BOM:524717:
Current Ratio: 3.28 (near median its 10-year median of 3.17)
GF Value™: ₹144.74 vs. price of ₹400.95 (177% above fair value)
Industry Position: 15.5% below the Biotechnology median (#777 of 1411)
No single metric tells the full story. See the BOM:524717 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Titan Biotech Ltd is a manufacturer and exporter of biological products. It manufactures biological products such as peptone, malt extract, yeast extract, liver extract, bile extract, culture media, laboratory chemicals, plant growth promoters, and others. The biological products have applications in the field of pharmaceutical, nutraceutical, food and beverages, biotechnology and fermentation, cosmetic, veterinary and animal feed, agriculture industries, and others. The company's business activity falls within a single primary business segment, which is the business of Biological Products. The firm sells its products in India and also exports internationally, of which the majority of the revenue is derived from the sales made in India.
58GF Score
Get the complete analysis for BOM:524717
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524717 has been successfully added to your 
